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Abstract
Background: Absorption of antigens onto chitosan microparticles via electrostatic interaction is
a common and relatively mild process suitable for mucosal vaccine. In order to increase the stability
of antigens and prevent an immediate desorption of antigens from chitosan carriers in
gastrointestinal tract, coating onto BSA loaded chitosan microparticles with sodium alginate was
performed by layer-by-layer technology to meet the requirement of mucosal vaccine.
Results: The prepared alginate coated BSA loaded chitosan microparticles had loading efficiency
(LE) of 60% and loading capacity (LC) of 6% with mean diameter of about 1 μm. When the weight
ratio of alginate/chitosan microparticles was greater than 2, the stable system could be obtained.
The rapid charge inversion of BSA loaded chitosan microparticles (from +27 mv to -27.8 mv) was
observed during the coating procedure which indicated the presence of alginate layer on the
chitosan microparticles surfaces. According to the results obtained by scanning electron
microscopy (SEM), the core-shell structure of BSA loaded chitosan microparticles was observed.
Meanwhile, in vitro release study indicated that the initial burst release of BSA from alginate coated
chitosan microparticles was lower than that observed from uncoated chitosan microparticles (40%
in 8 h vs. about 84% in 0.5 h). SDS-polyacrylamide gel electrophoresis (SDS-PAGE) assay showed
that alginate coating onto chitosan microparticles could effectively protect the BSA from
degradation or hydrolysis in acidic condition for at least 2 h. The structural integrity of alginate
modified chitosan microparticles incubated in PBS for 24 h was investigated by FTIR.
Conclusion: The prepared alginate coated chitosan microparticles, with mean diameter of about
1 μm, was suitable for oral mucosal vaccine. Moreover, alginate coating onto the surface of chitosan
microparticles could modulate the release behavior of BSA from alginate coated chitosan
microparticles and could effectively protect model protein (BSA) from degradation in acidic
medium in vitro for at least 2 h. In all, the prepared alginate coated chitosan microparticles might be
an effective vehicle for oral administration of antigens.
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Background
Development of an oral antigens (protein, and etc) deliv-
ery system for mucosal vaccine is a meaningful challenge
for pharmaceutical scientists. The instability and poor
absorption of antigens in gastrointestinal tract is major
obstacles in the development of oral antigen delivery sys-
tem for mucosal vaccine. Problems such as acid degrada-
tion in stomach, poor permeability across the
gastrointestinal mucosa and the first-pass metabolism
greatly limited the uptake of antigens by M-cell which is
very important step for immune response [1,2]. To over-
come the above-mentioned obstacles, several strategies,
including liposomes [3-5], micro/nanoparticles [6-8],
micro/nanoemulsion [9], and etc, have been explored to
encapsulate antigens for the mucosal vaccine. Among
these strategies, micro/nanoparticles made of biodegrada-
ble natural polymer have gained considerable interest in
the past decades. One important aspect is that some natu-
ral polymers, especially chitosan, haves been demon-
strated that could enhance the immunogenicity of poor
immune response antigens in the form of solution and
micro/nanoparticles [10,11].
Chitosan, as a cationic polysaccharide, has gained increas-
ing attention in pharmaceutical field due to its favorable
biological properties, such as non-toxicity, biodegradabil-
ity [1,12], mucoadhesive properties [13,14], and etc.
Additionally, chitosan micro/nanoparticles can be easily
prepared by ionic gelation method using tripolyphos-
phate (TPP) as precipitating agent [12,15]. The advantage
of this method was attributed to the mild condition with-
out the application of harmful organic solvent at room
temperature in the procedure, and also could efficiently
detain the bioactivity of macromolecules (protein, DNA
etc) during the encapsulation. In spite of all its superior
properties, chitosan has an apparent pKa of 5.6 and is
only soluble in acidic solutions. When incubated in phys-
iological fluid environment, chitosan will lose its capacity
of mucoadhesive properties and permeation enhancing
effect due to the deprotonation of chitosan, which would
make chitosan carriers lose its advantage compared with
other carriers for mucosal vaccine. Meanwhile, chitosan
has limited ability for controlling the release of encapsu-
lated macromolecule compounds because of its
hydrophilic nature and easy solubility in acidic medium
[1,16]. It might be an interesting method to overcome
these obstacles by coating acid-resistant polymer, such as
alginate sodium, onto the surface of chitosan microparti-
cles. As an anionic polysaccharide with favorable biologi-
cal properties, alginate can easily interact with cationic
chitosan microparticles to form the polyelectrolyte com-
plex via electrostatic interactions [3,17-19]. Additionally,
this coating procedure was performed at relatively mild
condition without using any organic solvent. This rela-
tively mild process has enabled not only proteins, but
cells and DNA to be incorporated into the chitosan/algi-
nate matrices with retention of biological activity [20].
In this work, we hope to develop a novel oral antigen car-
rier based on alginate coated chitosan microparticles to
meet the requirement of mucosal vaccine. Model protein
(BSA) was adopted to evaluate the properties of alginate
coated chitosan microparticles. In vitro release behavior of
BSA from chitosan microparticles and the stability of BSA
loaded chitosan microparticles against acidic condition
could be modified by alginate coating layer.
Methods
Materials
Chitosan with deacetylation (DA) of 92% and viscosity of
55 mpa.s (1% in 1% acetic acid, 20°C) was provided by
Sigma (USA). Sodium alginate with viscosity of 20–40 cp
(1% in distilled water) was obtained from Aldrich (USA).
Bovine serum albumin (BSA) was purchased from BoAo
Biochemical Company (Shanghai, China). Sodium
tripolyphosphate was bought from Sigma (USA), and
CaCl2  was bought from Chengdu KeLong Chemicals
(Chengdu, China). BCA™ kit was provided by Pierce
(USA). All other chemicals used in this paper were agent
grade. Ultrapure water from Milli-Q water system was
used to prepare the aqueous solutions.
Preparation of chitosan microparticles
Chitosan microparticles were prepared by the ionic gela-
tion of chitosan solution with anionic tripolyphosphate
(TPP). Briefly, chitosan was dissolved in 1% (v/v) acetic
acid aqueous solution at concentration of 5 mg/ml. Then,
TPP was dissolved in distilled water at the concentration
of 1 mg/ml. Subsequently, 9 ml of TPP solution was
added dropwisely into 18 ml of chitosan solution (5 mg/
ml), chitosan colloid microparticles were formed sponta-
neously under mild agitation at room temperature. Ten
minutes later, chitosan colloid microparticles were centri-
fuged (Beckman Coulter™, Avanti™ J-30I centrifuge, Ger-
many) at 9,500 rpm for 15 min. Then, the supernatant
was discarded and the deposit was re-dispersed in distilled
water for further use.
Loading bovine serum albumin (BSA) to chitosan 
microparticles
Colloid chitosan microparticles were re-dispersed in 25
ml of distilled water at concentration of 5 mg/ml under
continuous ultrasonication (Benchtop 20L, Medisafe, UK
Ltd, UK) to disaggregate the chitosan microparticles. The
loading procedure was performed by incubating different
concentrations of BSA with chitosan microparticles under
mild agitation at room temperature for 15 min. Loading
efficiency (LE) and loading capacity (LC) of BSA on chi-
tosan microparticles were detected in an indirect way by
determining the free BSA remained in the supernatantBMC Biotechnology 2008, 8:89 http://www.biomedcentral.com/1472-6750/8/89
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after the performance of centrifuge, and the method was
shown as following. One milliliter of BSA loaded chitosan
microparticles suspension was centrifuged (Centrifuge
5415D, Eppendorf, Germany) at 13,200 rpm for 20 min
and the amount of BSA in the supernatant was measured
by BCA™ kit [8]. The supernatant of blank chitosan micro-
particles was adopted as the blank to correct the absorb-
ance reading value of the BSA-loaded chitosan
microparticles. The corrected optical density (OD) value
was then used to calculate the concentration of BSA in the
supernatant.
The loading efficiency (LE) and loading capacity (LC) val-
ues were calculated according to the following equations:
Preparation of alginate coated chitosan microparticles
BSA loaded chitosan microparticles suspensions with pH
value at 5.1 were added dropwisely into sodium alginate
solution (pH = 7.2) at concentration of 10 mg/ml under
mild agitation for 10 min. Then the suspension was cen-
trifuged at 3,400 rpm for 5 min, and the supernatant was
discarded. Finally, alginate coated chitosan microparticles
were re-dispersed into calcium chloride (CaCl2) aqueous
solution (pH = 7.0) at concentration of 0.524 mmol/L to
crosslink the alginate layer presents on the surface of chi-
tosan microparticles.
Morphological characterization, size and surface charge
The morphological characteristics of microparticles were
examined by scanning electron microscopy (JSM-5900LV,
JEOL, Japan). Microparticles were sputtered with gold and
maintained at room temperature for complete dryness
before the observation.
The particle size distribution was detected by laser diffrac-
tion (Nano-ZS 90, Malvern Instrument, UK; BT-2002
Laser Particle Size Analyzer, Dandong Bettersize Instru-
ments LTD, China). The zeta potential of particles was
examined by Malvern Zeta analyzer (Nano-ZS 90, Mal-
vern Instrument, UK) with ultrapure water as solvent (pH
= 7, 25°C). These measurements were run at least three
times with independent particle batches.
Protein release in vitro
In vitro release behavior of BSA from uncoated and algi-
nate coated chitosan microparticles were determined as
followed. One milliliter of microparticles suspension was
first centrifuged and the deposit was incubated in 1 ml of
phosphate buffer saline (PBS, pH7.4) in Eppendorf tube
(EP tube). Then, the EP tube was placed in an air shaker
bath at 100 rpm/min (at 37°C) for in vitro release. At
scheduled time, samples were centrifuged at 13,200 rpm
for 20 min and the supernatant was replaced with fresh
PBS (pre-warmed to 37°C). The amount of BSA presented
in the supernatant was determined by BCA™ kit as
described in section 2.3. According to protocol, the
amount of BSA released was expressed as a percentage of
total BSA encapsulated in chitosan microparticles as cal-
culated from the LE value.In vitro release experiments were
repeated three times.
Acidic degradation protection assay
Different formulations of chitosan microparticles (BSA
loaded chitosan microparticles and alginate coated BSA
loaded chitosan microparticles) were first centrifuged at
13,000 rpm for 20 min and the supernatant was dis-
carded. Then, the deposition was incubated with 0.5 ml of
HCl (0.01 M) in air shaker bath at 37°C for 2 h. Finally,
the reaction was stopped by 0.5 ml of aqueous NaOH
(0.01 M) solution. These systems were sustained release
for another 24 h with addition of PBS to final volume at 4
ml. Twenty four hours later, the supernatant containing
released BSA was collected and analyzed by SDS-polyacr-
ylamide gel electrophoresis (SDS-PAGE). The pure BSA
solution was designed as the control.
Fourier transform infra-red (FTIR) measurements
FTIR measurements were taken at room temperature using
NICOLET 200SXV Infrared Spectrophotometer (USA).
Alginate coated chitosan microparticles at 0 h and 24 h of
release test in PBS (pH = 7.4) were centrifuged and
washed with ultrapure water, finally freeze-dried over-
night before the detection.
Results and discussion
Preparation of alginate coated BSA loaded chitosan 
microparticles
In this article, we prepared alginate coated chitosan
microparticles by layer-by-layer technology to meet the
requirement of oral administration of antigen for mucosal
vaccine. BSA with isoelectric point (PI) of 4.8 was nega-
tively charged when pH>4.8, which could easily absorb
cationic chitosan microparticle at aqueous solution (pH =
7) via electrostatic interaction and was selected as the
model protein to evaluate the properties of alginate
coated chitosan microparticles. This procedure could be
divided into three parts, preparation of the chitosan
microparticles, loading of BSA onto chitosan microparti-
cles, and finally coating of BSA loaded chitosan micropar-
ticles with sodium alginate. Chitosan microparticles were
prepared by ionic gelation method using sodium
tripolyphosphate (TPP) as precipitating agent that has
been described by several authors [12,15]. According to
Table 1, the mean particle size of prepared chitosan
microparticles was about 300 nm and the PDI was 0.309.
LE
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Then, chitosan microparticles were incubated in aqueous
solution with different BSA concentrations at a relatively
mild condition to obtain suitable loading efficiency (LE)
and loading capacity (LC). Finally, alginate was intro-
duced to coat onto surface of BSA loaded chitosan micro-
particles to increase the acidic resistance of BSA loaded
chitosan microparticles and to modulate the release
behavior of BSA from chitosan microparticles [4,17].
Effect of alginate/chitosan microparticles weight ratio on
the properties of microparticles was presented in Table 2.
As shown in Table 2, we could find that stable alginate
coated BSA loaded chitosan microparticles could be
obtained when the weight ratio of alginate/chitosan
microparticles was greater than 2. It might be explained by
the fact that the addition of small amount of alginate (the
weight ratio of alginate/chitosan microparticles smaller
than 2) to chitosan microparticles decreased the zeta
potential of microparticles and could facilitate the gela-
tion of chitosan and alginate resulting in agglomeration
or precipitation [21,22]. Meanwhile, when the weight
ratio of alginate/chitosan microparticles was greater than
2, the rapid charge inversion and gelation lead to the for-
mation of stable chitosan microparticles. Calcium ion
(CaCl2, 0.524 mM) was used as crosslinking agent to
strengthen and stabilize the particles [22].
Procedure of protein loading
Effect of BSA concentration
Cationic microparticles can easily absorb anionic protein
or DNA via electrostatic interaction [23,24]. Cationic chi-
tosan microparticles prepared in this work had a potent
capacity to absorb the model anionic protein (BSA) in
aqueous solution via electrostatic interaction. The
obtained chitosan microparticles at concentration of 5
mg/ml were adopted to evaluate particle size, zeta poten-
tial, loading efficiency, and loading capacity of alginate
coated BSA loaded chitosan microparticles. As presented
in Table 3, effect of BSA concentration on the properties
of chitosan microparticle were investigated. The mean
diameter of chitosan microparticles increased accompa-
nied with decrease in zeta potential when BSA concentra-
tion increased from 1 mg/ml to 8 mg/ml. This might be
attributed to the fact that negatively charged BSA absorbed
onto chitosan microparticles and neutralized part of zeta
potential of chitosan microparticles resulted in increase of
particle size and decrease of zeta potential [25]. Fig. 1
depicts the effect of BSA concentration on the loading effi-
ciency (LE) and loading capacity (LC) of chitosan micro-
particles. When the concentration of BSA was lower than
2 mg/ml, the loading efficiency was greater than 60%. The
loading efficiency significantly decreased to about 30 %
while BSA concentration was greater than 2 mg/ml. This
interesting phenomenon might be attributed to the satu-
rated absorption was achieved as BSA concentration at
about 2 mg/ml, the more addition of BSA was seldom
adsorbed onto chitosan microparticles which leaded to
the great decrease in loading efficiency (LE). Meanwhile,
loading capacity increased from 10% to 40% as the BSA
concentration increased from 1 mg/ml to 8 mg/ml.
Effect of alginate/chitosan microparticles weight ratio
Due to the electrostatic interaction between the positively
charged -NH3
+ of chitosan microparticles and negatively
charged -COO- of alginate, cationic BSA-loaded chitosan
microparticles could be easily modified with anionic algi-
nate in aqueous solution via electrostatic interaction [26].
However, the addition of anionic alginate to cationic BSA
loaded chitosan microparticles would replace some of
BSA absorption on the chitosan microparticles due to the
competitive electronic interaction [21]. According to Fig.
2, we could find that the loading efficiency (LE) of BSA on
chitosan microparticles increased with decrease in algi-
Table 1: The size and zeta potential of alginate/BSA/chitosan system
Sample Mean particles size (nm) PDI Zeta potential (mV)
Blank chitosan microparticles a 301.8 0.309 +45.2
BSA-loaded chitosan particles b 404 0.472 +27.1
Alginate coated BSA loaded chitosan microparticles c 1324 0.450 -27.8
a chitosan 5 mg/ml, TPP 1 mg/ml.
b chitosan 5 mg/ml, TPP 1 mg/ml, BSA 2 mg/ml.
c chitosan 5 mg/ml, TPP 1 mg/ml, BSA 2 mg/ml, alginate 10 mg/ml.
Table 2: Effect of alginate/chitosan microparticles weight ratio on the properties of alginate -chitosan microparticles formulation
Alginate/chitosan microparticles weight ratio Mean particles size (nm)
1:1 Immediately precipitation
2:1 2722 (partially precipitation)
3:1 1324
4:1 1021BMC Biotechnology 2008, 8:89 http://www.biomedcentral.com/1472-6750/8/89
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nate/chitosan microparticles weight ratio until the mass
ratio of alginate/chitosan microparticles was smaller than
2, but the precipitation of chitosan microparticles was
also observed. The zeta potential of colloidal chitosan
microparticles is an important factor for the stability of
particles. Generally, the higher zeta potential of particles
led to more stability of colloidal particles, and the lower
zeta potential of particles induced agglomeration of col-
loidal particles [12,21]. The observed precipitation of sys-
tem was probably caused by the decrease in zeta potential
(from +27 mv to -0.4 mv) and the gelation of chitosan
with addition of alginate. As the precipitation proceeded,
the higher LE was observed which might be attributed to
co-precipitation of BSA because of the gelation of chitosan
and alginate. However, stable colloidal microparticle sys-
tem (no precipitation observed) could be obtained when
the weight ratio of alginate/chitosan microparticles was
greater than 2, which might be explained by that the rapid
charge inversion and coating process of microparticles
(from +27 mv to -27.8 mv) leading to the stable system
Table 3: The mean particles size and zeta potential of BSA loaded chitosan microparticles
Sample BSA concentration (mg/ml) Mean particle size (nm) PDI Zeta potential (mV)
Chitosan microparticles at concentration of 5 mg/ml 1 380.8 0.393 +34.0
2 404.0 0.472 +27.1
4 420.3 0.450 +22.5
8 464.1 0.499 +12.7
Effect of different BSA concentrations on the loading efficiency (LE) and loading capacity (LC) of chitosan microparticles Figure 1
Effect of different BSA concentrations on the loading efficiency (LE) and loading capacity (LC) of chitosan 
microparticles.BMC Biotechnology 2008, 8:89 http://www.biomedcentral.com/1472-6750/8/89
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formed. However, the loading efficiency (LE) and loading
capacity (LC) of BSA on chitosan microparticles decreased
due to the competitive adsorption between alginate and
BSA resulting in some BSA desorption from chitosan
microparticles [21,27].
Characterization of chitosan microparticles
The obtained chitosan microparticles and alginate coated
BSA loaded chitosan microparticles were characterized by
SEM and laser diffraction. Two typical scanning electron
microphotographs of chitosan microparticles and alginate
coated BSA loaded chitosan microparticles were presented
in Fig. 3(A–B), respectively. According to Fig. 3(A), chi-
tosan microparticles were almost irregular spherical with
size ranging from 50 to 300 nm. It was also observed that
some small chitosan microparticles fused into large ones.
The result detected by Malvern Instrument indicated that
the average size of chitosan microparticles was about 300
nm and zeta potential was +45.2 mv (Table 2). The size
distribution of chitosan microparticles was presented in
Fig. 4(A), which indicated that well dispersed chitosan
microparticles were prepared. As shown in Fig. 3(B), SEM
photograph of alginate coated BSA loaded chitosan
microparticles show that the mean size of microparticles
was about 1 μm which was larger than BSA loaded chi-
tosan microparticles due to the coating microparticles
with alginate and the morphology of alginate coated BSA
loaded chitosan microparticles was shown to have core-
shell structure which indicated that the sodium alginate
was successfully coated on the surface of BSA loaded chi-
tosan microparticles core. Here, we also found that some
particles were adhered together. The size distribution of
alginate coated BSA loaded chitosan microparticles was
presented in Fig. 4(B). During the coating procedure, the
inversion of the zeta potential was observed by the Mal-
vern Instrument. After complete coating of alginate on
Effect of alginate/chitosan microparticles weight ratio on loading efficiency (LE) of alginate coated chitosan microparticles Figure 2
Effect of alginate/chitosan microparticles weight ratio on loading efficiency (LE) of alginate coated chitosan 
microparticles.BMC Biotechnology 2008, 8:89 http://www.biomedcentral.com/1472-6750/8/89
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chitosan microparticles core, the zeta potential of chi-
tosan microparticles was about -27.8 mv (Table 1), which
also implied the presence of alginate layer on the surface
of chitosan microparticles.
Protein release in vitro
The release profiles of BSA from uncoated and alginate
coated chitosan microparticles at phosphate buffer (PBS,
pH7.4) were shown in Fig. 5. As depicted in Fig. 5, the ini-
tial burst release (about 84%) of BSA from uncoated chi-
tosan microparticles occurred in the first 0.5 h, followed
by release of 95.5% in 2 days. The burst release might be
attributed to the fact that BSA macromolecules were
loosely bound onto chitosan microparticles by ionic inter-
action which could be easily desorbed at ionic environ-
ment [27]. However, alginate modified chitosan
microparticle could increase the stability of chitosan
microparticles in the PBS at 37°C which resulted in
extended release of BSA, only about 40% of BSA released
in 8 h. And 48 h later, there was still about 50% of BSA
retained in the alginate coated chitosan microparticles.
The total ratio of BSA released from the alginate coated
SEM images of chitosan microparticles (A) and alginate coated BSA loaded chitosan microparticles (B) Figure 3
SEM images of chitosan microparticles (A) and alginate coated BSA loaded chitosan microparticles (B).
The particle size distribution of chitosan microparticles (A), and alginate coated BSA loaded chitosan microparticles (B) Figure 4
The particle size distribution of chitosan microparticles (A), and alginate coated BSA loaded chitosan micro-
particles (B).BMC Biotechnology 2008, 8:89 http://www.biomedcentral.com/1472-6750/8/89
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chitosan microparticles in 48 h was much less than that
observed from uncoated chitosan microparticles. The
longer release time and slower release rate of BSA from
alginate coated chitosan microparticles might be
explained by that there are strong interaction between
polymers (chitosan and alginate) and BSA [28]. Addition-
ally, the presence of alginate layer could slow down the
diffusion of BSA from the system which also prolong the
release time of BSA from system. But, due to both the deg-
radation and erosion of matrix, the BSA might be released
from the alginate/BSA/chitosan formulation in an
extended profile [29]. This release behavior studies indi-
cated that coating of alginate onto chitosan microparticles
could improve the stability of chitosan microparticles in
PBS and modify the release behavior of BSA from these
alginate coated chitosan microparticles.
Acidic degradation protection
In this paper, we hope to design an oral antigens delivery
system for mucosal vaccine. As we know, pH value of gas-
tric fluid is approximately 2 which will destroy the integ-
rity and structure of antigens (protein, DNA, etc) after the
oral administration without any protection. Therefore, it
is very important for us to develop an antigen carrier
based on chitosan and alginate that can effectively avoid
the acidic degradation of encapsulated antigen before it
reached the target site. Here, BSA released from uncoated
and alginate coated chitosan microparticles under acidic
medium (pH2.0) and PBS medium (pH7.4) was analyzed
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
According to Fig. 6, molecular weight marker was shown
in Lane 5, and the BSA incubated with PBS (pH7.4) for 24
h exhibited a clear band at about 66 KD (Lane 4). How-
In vitro release profiles of BSA from uncoated chitosan microparticles (Black) and alginate coated chitosan microparticles (Red)  in PBS (pH7.4) at 37°C Figure 5
In vitrorelease profiles of BSA from uncoated chitosan microparticles (Black) and alginate coated chitosan 
microparticles (Red) in PBS (pH7.4) at 37°C.BMC Biotechnology 2008, 8:89 http://www.biomedcentral.com/1472-6750/8/89
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ever, BSA pretreated with 0.01 M HCl for 2 h then incu-
bated with PBS for 24 h had a faint band at 66 KD (Lane
3) which indicated the serious degradation or hydrolysis
of BSA in acidic medium. The SDS-PAGE gel banding pat-
terns of BSA released from uncoated and alginate coated
chitosan microparticles with HCl (pH2.0) pretreatment
for 2 h and then sustained release in PBS for 24 h are
shown in Lane 1 and Lane 2, respectively. It is seen that
BSA from uncoated chitosan microparticles had a very
weak band at 66 KD (Lane 1) which indicated that the
BSA underwent hydrolysis/degradation in spite of pres-
ence of chitosan microparticles (pH2.0). Meanwhile, we
also observed the flocculent precipitate of system with the
addition of sodium hydrate to BSA loaded chitosan
microparticles which implied the dissolution of chitosan
microparticles in acidic condition (pH2). However, BSA
from alginate coated chitosan microparticles had a clear
band at about 66 KD (Lane 2), which implied that algi-
nate coating of chitosan microparticles could effectively
protect BSA from hydrolysis/degradation at acidic
medium for at least 2 h. So, the obtained alginate coated
chitosan microparticles might be an effective oral anti-
genic carrier for mucosal vaccine
Fourier transform infra-red (FTIR) measurements
Stability of alginate coated chitosan microparticles in PBS
was investigated using FTIR spectroscopy. According to
Fig. 7, alginate coated chitosan microparticles at 0 h and
24 h of release test showed similar spectra. The peaks at
3435, 1640, 1415 and 1109 cm-1 were due to the stretch-
ing of O-H, COO-(asymmetric), COO-(symmetric), and
C-O-C, respectively. Compared with FTIR spectrum of
alginate modified chitosan microparticles at 0 h of release
test, the shift of COO- peaks at 1635 and 1415 cm-1 to
higher wavenumber (1640 and 1418 cm-1 respectively), as
well as the decrease in intensity, was observed in alginate
modified chitosan microparticles at 24 h of release test in
PBS, which indicated that ionic desorption between COO-
of alginate and calcium ions or NH3
+ of chitosan was
occurred at 24 h of release test [30,31].
Conclusion
The prepared alginate coated chitosan microparticles,
with mean diameter of about 1 μm, was suitable for oral
administration. Moreover, alginate coating onto surface
of chitosan microparticles could modulate the release
behavior of BSA from alginate coated chitosan micropar-
ticles and could effectively protect model protein (BSA)
from degradation against acidic medium (pH2) in vitro at
least for 2 hours. According to FTIR, some alginate on sur-
face of chitosan microparticles at 24 h of release test has
been dissolved into PBS. Based on the information dem-
onstrated, the prepared alginate coated chitosan micro-
particles might be an effective vehicle for oral
administration of antigens.
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